Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of L-Adrenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.96 |
| ▸ | TSHR | P16473 | 5/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL16667632 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL41370 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL31238229 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL9614373 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL31267207 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL4980185 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL25041 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL28311143 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL3111795 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL660960 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139664-A1 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20050043408-A1 | Anti-glycation agents for preventing age- diabetes- and smoking-related complications | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2005-02-24 | — | — | US | disclosed |
| EP-1435930-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032969-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043408-A1 | Anti-glycation agents for preventing age- diabetes- and smoking-related complications | AGER, GID4, GALE | ADRB2 82/4885ADRB1 40/4885ADRB3 61/4885 |
| US-20080139664-A1 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | AGER, GID4, GALE | ADRB2 53/4885ADRB1 29/4885ADRB3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.